13D Filing: OrbiMed Advisors and Corvus Pharmaceuticals Inc (CRVS)

Page 3 of 12

Page 3 of 12 – SEC Filing

SCHEDULE 13D
CUSIP No.  221015100
1
NAME OF REPORTING PERSONS
OrbiMed Capital GP V LLC
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) o
(b) o
3
SEC USE ONLY
4
SOURCE OF FUNDS (See Instructions)
AF
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
o
6
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
7
SOLE VOTING POWER
0
8
SHARED VOTING POWER
5,967,584
9
SOLE DISPOSITIVE POWER
0
10
SHARED DISPOSITIVE POWER
5,967,584
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
5,967,584
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
o
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
20.47%*
14
TYPE OF REPORTING PERSON (See Instructions)
OO
_______________________
*This percentage is calculated based upon 29,158,897 shares of the Issuer’s Common Stock (defined below) outstanding, as set forth in the Issuer’s Rule 424(b)(5) Prospectus filed with the SEC (defined below) on March 9, 2018 and after giving effect to the additional 1,058,823 shares of Common Stock issued and sold by the Issuer to the underwriters pursuant to the underwriters’ option.

Follow Corvus Pharmaceuticals Inc.

Page 3 of 12